![Anticipation for Ethereum [ETH] 2.0 rises as metric reaches all-time high](http://thecryptodays.com/wp-content/uploads/2023/01/ethereum-wale-1000x600-75x75.jpg)
Digital health company Ada Health has raised $30 million as part of an extension of its Series B round from last year, bringing the total funding to $120 million.
The Berlin-based company announced the news on its website Thursday (Feb. 10), saying the funding would let it accelerate its growth and strengthen its foothold in the U.S. Ada has spoken in the past about becoming the world’s leading personalized operating system for health.
The funding comes amid “a period of strong growth in North America, where Ada has forged collaborations with leading health systems and care providers, while continuing existing client partnerships internationally with the likes of Bayer, Novartis and Sutter Health,” Ada said.
Bayer’s fundraising arm led the initial Series B round last year, taking in $90 million. The latest round was led by Farallon Capital, Red River West and Bertelsmann Investments.
Read more: Germany’s Ada Health Raises $90 Million Series B Led By Bayer
Ada’s health assessment and care navigation platform combines medical knowledge with artificial intelligence (AI) to help users understand their symptoms and find the right care.
Ada says its consumer app has become the “world’s most popular and highest-rated symptom assessment app,” handling more than over 26 million assessments since its launch and earning 300,000 five-star ratings around the world.
“Today’s investment will enable us to double down on our growth in the U.S. and in other key geographies, while continuing to develop our suite of AI-powered solutions, strike new partnerships, and create a truly personalized operating system for health,” said Daniel Nathrath, the company’s CEO.
The company says it aims to build on its AI capabilities by developing a personalized operating system for health that connects multiple external data sources to give users actionable insights and a complete view of their personal health journey.
“As a company, our goal is to improve healthcare outcomes for more than 1 billion people around the world. Covid-19 has highlighted the need for greater, faster change within healthcare, and we are seeing a growing demand from health systems, insurers and life sciences organizations for innovative ways to help transform health journeys and drive better outcomes for patients, clinicians and providers,” Nathrath said.
